When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PFE - Pfizer and Merck KGaA's Bavencio flunks late-stage GEJ study
Pfizer Inc.
A Phase 3 clinical trial, JAVELIN Gastric 100, evaluating Pfizer (NYSE:PFE) and alliance partner Merck KGaA's (OTCPK:MKGAY) Bavencio (avelumab) as first-line maintenance therapy following induction chemotherapy in patients with unresectable, locally advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer versus standard of care failed to achieve the primary endpoint of overall survival (OS).
More news on: Pfizer Inc., Merck KGaA ADR, Healthcare stocks news,